# Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss

> **NCT02822482** · PHASE1,PHASE2 · TERMINATED · sponsor: **UNICANCER** · enrollment: 11 (actual)

## Conditions studied

- Carcinoma, Squamous Cell of Head and Neck

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT02822482
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2019-10-09
- **Final completion:** 2019-10-09
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** futilty of the treatment
- **Last updated:** 2021-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02822482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02822482, "Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02822482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*